Articles
<![CDATA[Hubungan Kadar Apolipoprotein B dengan Tingkat Keparahan Stroke Iskemik ]]>
<![CDATA[Jabbar, Ridho Ahmad]]>;
<![CDATA[Indra, Syarif]]>;
<![CDATA[Dedi Sutia]]>;
<![CDATA[Syafrita, Yuliarni]]>;
<![CDATA[Susanti, Restu]]>;
<![CDATA[Putri, Fanny Adhy]]>
<![CDATA[ Jurnal Ners Vol. 9 No. 4 (2025): OKTOBER 2025 ]]>
Publisher : <![CDATA[Universitas Pahlawan Tuanku Tambusai ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.31004/jn.v9i4.49865
<![CDATA[Background: Stroke is a leading cause of disability and the second leading cause of death worldwide. Ischemic stroke occurs due to vascular occlusion that restricts blood supply to the brain. Apolipoprotein B (ApoB) is the main component of atherogenic lipoprotein particles, which plays a role in the pathogenesis of atherosclerosis. The NIHSS is recommended as a valid and accessible tool for assessing the severity of acute stroke. Although ApoB has been studied as a lipid biomarker, evidence regarding its association with the severity of ischemic stroke remains limited. Methods: This cross-sectional study included 72 ischemic stroke patients with onset <72 hours who were admitted to Dr. M. Djamil General Hospital, Padang, from February 2025 to July 2025. Data were collected through interviews, physical examinations, supporting investigations, and laboratory tests. ApoB levels were measured using the ELISA method, and stroke severity was assessed using the NIHSS. Data analysis was performed using SPSS version 30.0, with statistical significance set at p < 0.05. Results: The mean Apolipoprotein B level was 105.25 mg/dL. Based on NIHSS assessment, patients with moderate stroke severity accounted for 43.1%, followed by mild stroke (37.5%) and severe stroke (19.4%). Statistical analysis showed no significant association between Apolipoprotein B levels and ischemic stroke severity (p = 0.614). Conclusion: There was no association between Apolipoprotein B levels and ischemic stroke severity.]]>
<![CDATA[The Association between NLR and TGF-β with Acute Ischemic Stroke Severity with and without Thrombolysis ]]>
<![CDATA[Marliana, Lesti]]>;
<![CDATA[Indra, Syarif]]>;
<![CDATA[Sutia, Dedi]]>;
<![CDATA[Syafrita, Yuliarni]]>;
<![CDATA[Susanti, Restu]]>;
<![CDATA[Putri, Fanny Adhy]]>
<![CDATA[ Jurnal Ners Vol. 9 No. 4 (2025): OKTOBER 2025 ]]>
Publisher : <![CDATA[Universitas Pahlawan Tuanku Tambusai ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.31004/jn.v9i4.49866
<![CDATA[Acute ischemic stroke is a leading cause of mortality worldwide. Thrombolysis is the main treatment in the acute phase; however, clinical outcomes remain variable. Inflammatory markers such as the NLR and TGF-β1 may reflect inflammatory activity and tissue repair, yet their relationship with stroke severity is not fully established. This study aimed to evaluate the association of NLR and TGF-β1 with acute ischemic stroke severity in patients with and without thrombolysis. A cross-sectional study was conducted in the neurology ward of Dr. M. Djamil General Hospital, Padang. Patients with acute ischemic stroke, either treated with thrombolysis or not, were included. NLR and TGF-β1 were measured at 24 hours after onset, while stroke severity was assessed using the NIHSS at 24 hours. A total of 25 thrombolyzed and 25 non-thrombolyzed patients were enrolled. The results showed no significant association between NLR and stroke severity in either the thrombolysis (p=0.123) or non-thrombolysis group (p=0.257). In contrast, TGF-β1 was significantly associated with stroke severity in both groups (p<0.001 and p=0.002, respectively). In conclusion, TGF-β1 correlates with acute ischemic stroke severity regardless of thrombolysis, while NLR shows no significant association.]]>
<![CDATA[Hubungan Kadar Neuron Specific Enolase Serum dengan Subtipe dan Tingkat Keparahan pada Pasien Stroke Iskemik Akut ]]>
<![CDATA[Prandana, Dhani Arief]]>;
<![CDATA[Indra, Syarif]]>;
<![CDATA[Sutia, Dedi]]>;
<![CDATA[Susanti, Restu]]>;
<![CDATA[Putri, Fanny Adhy]]>;
<![CDATA[Dinata, Gunawan Septa]]>
<![CDATA[ Jurnal Ners Vol. 9 No. 4 (2025): OKTOBER 2025 ]]>
Publisher : <![CDATA[Universitas Pahlawan Tuanku Tambusai ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.31004/jn.v9i4.49867
<![CDATA[Background: Acute ischemic stroke is a serious medical condition with potentially life-threatening consequences. It occurs when cerebral blood flow is obstructed by vascular occlusion, resulting in brain tissue injury. Neuron Specific Enolase (NSE) is a biomarker used to assess the extent of neuronal damage in patients with ischemic stroke. This study aims to evaluate the association between serum NSE levels, stroke subtypes, and stroke severity in patients with acute ischemic stroke. Methods: This observational study employed a cross-sectional design and included 67 patients with acute ischemic stroke. Serum NSE levels were measured using the ELISA method. Stroke subtypes were determined according to the TOAST classification, and stroke severity was assessed using the NIHSS score. Statistical analysis was performed to evaluate the association between serum NSE levels, stroke subtypes, and severity. Results: The mean serum NSE level was 14.038 ng/ml. Large artery atherosclerosis (LAA) was the most prevalent subtype with a moderate severity level. Statistical analysis showed a significant association between serum NSE levels and stroke subtype (p = 0.021) and severity (p = 0.034) in patients with acute ischemic stroke. Conclusion: Serum NSE levels are significantly associated with both stroke subtype and severity in patients with acute ischemic stroke.]]>
<![CDATA[Migraine And Pregnancy: What Should We Know ]]>
<![CDATA[Susanti, Restu]]>;
<![CDATA[Muhammad, Syamel]]>
<![CDATA[ Andalas Obstetrics And Gynecology Journal Vol. 4 No. 2 (2020) ]]>
Publisher : <![CDATA[Fakultas Kedokteran Universitas Andalas ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.25077/aoj.4.2.251-260.2020
<![CDATA[Migraine is a common headache characterized by unilateral throbbing-like headache and pulsating in nature and sometimes associated with aura. Migraine is a disabling disorder that among adults is more prevalent among women than men. It is primary headache that is often found in pregnancy. Migraine is a common disorder in women of childbearing age, and usually requires pharmacological treatment. Migraine can be considered an important risk factor for hypertensive and vascular diseases during pregnancy. Migraine therapy in pregnancy is very challenging, it must taken into a consideration about the health of the mother and fetus. Several effective antimigraine medications are reasonably safe for use by pregnant and breastfeeding women. Prophylactic theraphy should be given to patient with recurrent migraine attacks in pregnancy. Nonpharmacological strategies are always first-line treatment options for mild migraine, and should also be used complementarily whenever pharmacological treatment is required. Women with migraine should be offered periconceptional counselling to promote a safe and healthy pregnancy. Keywords: migraine; pregnancy; therapy]]>
<![CDATA[Selecting Hormonal Contraceptives in Women Taking Antiepileptic Drugs : Review of Literature and Practical Recommendations ]]>
<![CDATA[Permana, Hendra]]>;
<![CDATA[Susanti, Restu]]>;
<![CDATA[Muhammad, Syamel]]>
<![CDATA[ Andalas Obstetrics And Gynecology Journal Vol. 4 No. 2 (2020) ]]>
Publisher : <![CDATA[Fakultas Kedokteran Universitas Andalas ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.25077/aoj.4.2.231-240.2020
<![CDATA[Contraception is a very important issue in women with epilepsy, since very broad questions taken in applying it to prevent unplanned pregnancy. The choice of contraceptive methods must be related to how the mechanism of action of antiepileptic drugs (AEDs), the contraceptive itself, and both interactions. Hormonal contraception can induce metabolism of AEDs and lead to increasing of seizure frequency, and in the other hand AEDs may decrease the blood levels of hormonal contraception. Therefore, physician must consider the type of contraception being used before prescribing AEDs. Additionally, they should emphasize the interaction between them in counseling, to assure that women with epilepsy have time to decide which type will be best use for them. This challenging matter needs better recommendation for practice, both neurologist and gynecologist.Keywords: antiepileptic drug, contraception, women with epilepsy]]>
<![CDATA[How far is Covid-19 Pandemic Situation Influence Surgical Treatment in Gynecology Cancer? : Comprehensive Review for Indonesian ]]>
<![CDATA[Muhammad, Syamel]]>;
<![CDATA[Susanti, Restu]]>
<![CDATA[ Andalas Obstetrics And Gynecology Journal Vol. 4 No. 2 (2020) ]]>
Publisher : <![CDATA[Fakultas Kedokteran Universitas Andalas ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.25077/aoj.4.2.203-217.2020
<![CDATA[Corona virus disease 2019 (COVID-19) was declared as global pandemic and caused devastating crisis in society. Despite of the growing pandemic, high quality medical services toward gynaecologic oncology patients must continue without overlooking the safety of medical staffs. Reducing risk is crucial and achieved by limiting high risk situations. The decision to perform or postpone surgery should be made based on the type and stage of the disease, medical condition of the patient, area census of COVID-19 cases, COVID-associated risks, and available logistic support including adjuvant treatment services. There are several recommendation for gynaecology cancer treatment published by several countries. However, those guidelines cannot be applied to every country across the globe because of the different situations of COVID-19 therefore we proposed guidelines for Indonesia. Surgical management for confiermed COVID-19 case should be postponed for at least 15 days for nonemergency cases. Surgery must be performed immediately for emergency cases such as Haemorrhage with unstable vital status refractory to transfusion, viscus perforation, signs of bowel obstruction refractory to conservative treatment, closed loop bowel or large bowel obstruction, hydatiform mole for live saving procedure. Â Keywords: COVID-19, gynaecology cancer, surgical management]]>
<![CDATA[Menstrual Migraine : How Hormones Impact Migraine ]]>
<![CDATA[Susanti, Restu]]>;
<![CDATA[Muhammad, Syamel]]>
<![CDATA[ Andalas Obstetrics And Gynecology Journal Vol. 5 No. 1 (2021) ]]>
Publisher : <![CDATA[Fakultas Kedokteran Universitas Andalas ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.25077/aoj.5.1.9-17.2021
<![CDATA[Menstrual Migraine is divided into 2 subtypes: Menstrually Related Migraine (MRM) and Pure Menstrual Migraines (PMM). In PMM symptoms do not occur outside the menstrual cycle while MRM, symptoms can occur at other times apart from the menstrual cycle. The occurrence of menstrual migraines is related to the female hormones cycle in the form of the decrease in estrogen levels which usually occurs a week before the onset of menstruation. The mechanism is unclear, but it is thought that a decrease in estrogen levels can trigger decrease in serotonin levels, causing cranial vasodilation and sensitization of the trigeminal nerve. Â Keywords: menstrual migraine, hormones]]>
<![CDATA[Relationship between Serum p-Tau Levels and Impaired Cognitive Function in Type 2 Diabetes Mellitus ]]>
<![CDATA[Riandini, Isnu Lucky]]>;
<![CDATA[Yuliarni Syafrita]]>;
<![CDATA[Restu Susanti]]>;
<![CDATA[Syarif Indra]]>;
<![CDATA[Lydia Susanti]]>;
<![CDATA[Fanny Adhy Putri]]>;
<![CDATA[Reno Bestari]]>
<![CDATA[ Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 8 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research ]]>
Publisher : <![CDATA[HM Publisher ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.37275/bsm.v8i8.1041
<![CDATA[Background: Type 2 diabetes mellitus (Type 2 DM) is a metabolic disease that causes a global crisis that threatens health and the world economy. Impaired cognitive function is a key factor in reducing health-related quality of life in type 2 DM patients. Phosphorylated Tau (p-Tau) is a microtubule protein that functions in cell signaling, synaptic plasticity, and regulation of genome stability. A malfunction of p-Tau will cause disruption of cell signaling, which can result in impaired cognitive function. This study aims to assess the relationship between serum p-Tau levels and impaired cognitive function in type 2 diabetes mellitus patients. Methods: This research is an observational study, comparative analysis with a cross-sectional design with a sample of 60 type 2 diabetes mellitus patients who sought treatment at the endocrine polyclinic at Dr. M. Djamil General Hospital Padang. Cognitive function was assessed using MoCa-Ina. Serum p-Tau levels were measured using the ELISA method. Data analysis was carried out using SPSS. Results: The average serum p-Tau level in type 2 diabetes mellitus patients with impaired cognitive function was 542.9 pg/ml. The cut-off point for serum p-Tau levels which is associated with impaired cognitive function in type 2 diabetes mellitus patients is 517.2 pg/ml. There was a significant relationship between serum p-Tau levels and impaired cognitive function in type 2 diabetes mellitus patients (p=0.039). Conclusion: There is a significant relationship between serum p-Tau levels and impaired cognitive function in type 2 diabetes mellitus patients.]]>
<![CDATA[Study Analysis of Serum Phosphorylated Tau (P-Tau) Levels with Severity and Outcome in Traumatic Brain Injury Patients: A Single Center Observational Study at Dr. M. Djamil General Hospital, Padang, Indonesia ]]>
<![CDATA[Istiqomah]]>;
<![CDATA[Syafrita, Yuliarni]]>;
<![CDATA[Fanny Adhy Putri]]>;
<![CDATA[Syarif Indra]]>;
<![CDATA[Restu Susanti]]>;
<![CDATA[Reno Bestari]]>
<![CDATA[ Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 9 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research ]]>
Publisher : <![CDATA[HM Publisher ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.37275/bsm.v8i9.1060
<![CDATA[Background: Traumatic brain injury (TBI) is a global health problem that can cause death and disability in people of productive age. The diagnosis and assessment of TBI severity currently still rely on clinical examination and neuroimaging. However, limited access and cost of neuroimaging are obstacles in many health facilities. Therefore, blood-based biomarkers are needed that can help the diagnosis and prognosis of TBI. Phosphorylated Tau (p-tau) is a potential biomarker that can be measured in serum. This study aims to assess the relationship between serum p-tau levels and severity and outcome in TBI patients. Methods: This research is a comparative study with a cross-sectional design involving 70 TBI patients who came to the emergency room (ER) of Dr. M. Djamil General Hospital Padang. TBI severity was assessed using the Glasgow coma scale (GCS) and grouped into mild (GCS 13-15) and moderate to severe (GCS 3-12). Outcomes were assessed using the Glasgow outcome scale (GOS) and grouped into good (GOS 4-5) and poor (GOS 1-3). Serum p-tau levels were measured using the ELISA method. Data analysis was carried out using SPSS. Results: The median serum p-tau level in the mild TBI group was 165.84 ng/L (IQR 126.18-463.85), while in the moderate to severe TBI group, it was 177.68 ng/L (IQR 87.62-591 .93). There was a significant difference between serum p-tau levels in the mild and moderate to severe TBI groups (p=0.029). The median serum p-tau level in the good outcome group was 167.21 ng/L (IQR 87.62-463.85), while in the poor outcome group it was 187.04 ng/L (IQR 137.75-591.93). There was a significant difference between serum p-tau levels in the good and bad outcome groups (p=0.014). Conclusion: Serum p-tau levels have a significant relationship with severity and outcome in TBI patients. Elevated serum p-tau levels are associated with increased severity of TBI and poor outcomes. Further research is needed to confirm these findings and explore the potential of p-tau as a biomarker in TBI management.]]>
<![CDATA[Plasma pTau181 dan Gejala Neuropsikiatri pada Demensia Alzheimer: Sebuah Studi Cross-Sectional ]]>
<![CDATA[Fadhilah, Nailatul]]>;
<![CDATA[Syafrita, Yuliarni]]>;
<![CDATA[Susanti, Restu]]>;
<![CDATA[Indra, Syarif]]>;
<![CDATA[Susanti, Lydia]]>;
<![CDATA[Putri, Fanny Adhy]]>
<![CDATA[ Journal of Pharmaceutical and Sciences JPS Volume 8 Nomor 4 (2025) ]]>
Publisher : <![CDATA[Fakultas Farmasi Universitas Tjut Nyak Dhien ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.36490/journal-jps.com.v8i4.1143
<![CDATA[Alzheimer’s disease is the leading cause of dementia, marked by progressive cognitive decline and neuropsychiatric disturbances collectively known as behavioral and psychological symptoms of dementia (BPSD). Plasma phosphorylated tau at threonine-181 (pTau181) has emerged as a minimally invasive biomarker of tau-related neurodegeneration, but its association with BPSD remains uncertain. This study investigated the relationship between plasma pTau181 levels and BPSD in Alzheimer’s dementia. An analytical observational study with a cross-sectional design was conducted in patients clinically diagnosed with predefined eligibility criteria. Plasma pTau181 concentrations were measured using enzyme-linked immunosorbent assay (ELISA), while BPSD was assessed using the Neuropsychiatric Inventory Questionnaire (NPI-Q). Statistical analyses were performed to examine associations between plasma pTau181 and BPSD status. Plasma pTau181 levels ranged from 4.32 to 97.23 pg/mL, with a median plasma pTau181 level of 19.29 pg/mL (IQR: 11.81-25.05) in patients without BPSD and 20.67 pg/mL (IQR: 11.81-43.41) in those with BPSD. No significant differences in pTau181 levels were observed between patients with and without BPSD (p = 0.310). These findings suggest that plasma pTau181 may not be directly related to the presence of BPSD in Alzheimer’s dementia. While plasma pTau181 remains a promising biomarker of tau pathology, its predictive value for neuropsychiatric symptoms appears limited. Longitudinal studies are needed to explore its role in BPSD pathophysiology further.]]>
